17,261 trials
FGFR Inhibition, Pharmacokinetics, Biomarkers · ER+ Breast Cancer
Primary: Safety and Tolerability in Terms of Number of Patients With Adverse Events (Serious and Non-serious) — 5; 5; 12; 9 Participants
Prevention of Meningococcal Disease
Primary: Number of Subjects (2-10 Years of Age) With Human Serum Bactericidal Activity (hSBA) Titers ≥1:4 After Receiving Either MenACWY-CRM or MenACWY-PS Vaccine — 6; 1; 228…
Dental Caries · Dental Pulp Exposure
Primary: Comparison of MTA/FS Pulpotomy Versus RCT Treated Incisors With Acceptable Radiographic Outcome at 12 Months Post-procedure. — .97; .92 Proportion of incisors — p=.15
Acute Myeloid Leukemia With FLT3/ITD Mutation · Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 · Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
Primary: Overall Survival (OS) Rate — 62; 71 percentage of participants
Advanced Pancreatic Neuroendocrine Tumor · Locally Advanced Pancreatic Neuroendocrine Tumor · Pancreatic Gastrinoma
Primary: Progression Free Survival — 14.0; 16.7 months — p=0.12
Lung Cancer
Primary: To Establish Rate of Non-progressive Disease at 4 Months in Patients With Advanced NSCLC Who Have Been Designated PS2 by Their Treating Physician — 28 percentage of…
Lung Cancer
Primary: 8-Week Disease Control Rate — 58.2 percentage of participants
Malignant Melanoma
Primary: Number of Participants With Any Adverse Event, Adverse Events With Severity, Adverse Events Leading to Discontinuation — 346; 115; 15; 7 participants
Gastric Cancer Adenocarcinoma Metastatic
Primary: Progression-free Survival — 4.7; 5.1 months
Skin Carcinoma
Primary: Number of Participants With Reduction in the Observed Numbers of Basal Cell Carcinomas ≥ 9 mm² in Diameter — 5; 29 participants
Recurrent Prostate Cancer
Primary: Median Time to PSA Progression
Glioblastoma Multiforme · Anaplastic Astrocytoma
Primary: Safety of Twice a Day Oral 150 mg Erlotinib Dosing — 9 participants
Head and Neck Cancer · Colon Cancer
Primary: If Eribulin Mesylate, up to a Maximum Dose of 1.4 mg/m2 Day 1 and 8 of a 21 Day Cycle, Can be Safely Combined With Full Dose Cetuximab for Patients With Advanced Head…
HIV Infections
Primary: Person-years of Follow-up of Tenofovir 1% Gel and Vaginal Placebo Gel Arms — 1024; 1030 person-years
Focal Segmental Glomerulosclerosis
Primary: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. — 0; 0; 0.5; 0.25 proportion of participants with…